Cytori Therapeutics to Present at the BIOCOM Investor Conference
Posted on: Thursday, 9 November 2006, 09:00 CST
Cytori Therapeutics, Inc., (NASDAQ: CYTX) (Frankfurt: XMPA) announced today that it will present and provide an audio webcast of its corporate presentation at the BIOCOM Investor Conference, November 15th at 3:40 p.m. Pacific Standard Time (6:40 p.m. Eastern Standard Time).
A webcast of the presentation may be accessed under "Events & Webcasts" in the Investor Relations section of the Company's website at http://www.cytoritx.com. The webcast will be available live and by replay one hour after the presentation on the company's website and archived for 30 days.
About Cytori Therapeutics
Cytori Therapeutics, Inc., (NASDAQ: CYTX) (Frankfurt: XMPA) is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue, also known as fat. The Company's investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem and regenerative cells, Cytori has developed its proprietary Celution™ System to isolate and concentrate a patient's own stem and regenerative cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients.
Source: Business Wire
Related Articles
- Hollis-Eden Pharmaceuticals Updates Upcoming Investor Conference Presentations and Webcasts
- Technique for Rapidly Reprogramming Adult Cells Into Stem Cells Published in PLoS Biology
- Cytori Selected By Fraunhofer Society to Develop New Stem and Regenerative Cell-Based Treatments for Stroke
- PrimeGen Biotech Announces Non-Viral Reprogramming of Human Cells into Stem Cells
- Applied Micro Circuits Corporation Announces Schedule of Investor Conference Presentations and Webcasts
- Texas Instruments Presents Live Webcast on Designing Digital Video Systems Leveraging DaVinci(TM) Technology
- First Three Patients Treated in Adipose Stem and Regenerative Cell Clinical Safety and Feasibility Study for Breast Reconstruction; Represents First Clinical Use of Cytori's Regenerative Cell Processing System
- Cytori Therapeutics Reports Benefit of Adipose Stem and Regenerative Cells in Reconstructive Surgery From Preclinical Study
- Cytori Therapeutics Demonstrates Adipose Stem and Regenerative Cells Reduce Incidence of Arrhythmia After Heart Attacks in Preclinical Study
- Clinical Safety and Feasibility Study Initiated Using Adipose Stem and Regenerative Cells in Breast Reconstruction Procedures
 |
 |
User Comments (0)
RSS Feeds